REG - AstraZeneca PLC - AstraZeneca manufacturing investment in Maryland

AstraZenecaAnnouncement

24/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251124:nRSX6266Ia&default-theme=true

RNS Number : 6266I  AstraZeneca PLC  24 November 2025

24 November 2025

 

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting
2,600 jobs and catalysing economic growth

New capacity at AstraZeneca's Frederick and Gaithersburg facilities will
accelerate production of cancer, rare and chronic disease medicines

Fourth major US manufacturing investment announced this year, advancing
AstraZeneca's historic $50 billion commitment to medicines manufacturing and
R&D

 

AstraZeneca today announces plans to invest $2 billion to expand its
long-standing manufacturing footprint in Maryland. This includes a significant
expansion of its flagship biologics manufacturing facility in Frederick and
construction of a new state-of-the-art facility in Gaithersburg for the
development and clinical supply of innovative molecules to be used in clinical
trials. The investment will support 2,600 jobs across the two sites in the
state including the retention of local roles, construction activity, and the
creation of 300 highly skilled jobs.

 

The Frederick facility currently produces biologics, a type of medication used
across AstraZeneca's portfolio of cancer, auto immune, respiratory and rare
disease treatments. The planned expansion will nearly double commercial
manufacturing capacity, enabling increased supply of existing medicines and,
for the first time, production across the Company's rare disease portfolio.
It will create 200 highly skilled jobs and 900 construction roles and is
expected to be operational in 2029.

 

In parallel, AstraZeneca will build a new clinical manufacturing facility to
expand its footprint in Gaithersburg.  The facility, which will be fully
operational by 2029, will create an additional 100 jobs, retain 400 roles and
support a further 1,000 construction-related jobs.

 

Both the expanded facility in Frederick and the new facility in Gaithersburg
will leverage cutting-edge AI, automation and data analytics and be built to
the highest environmental standards.

 

Maryland Governor, Wes Moore, said: "AstraZeneca's commitment to Maryland
speaks to our unique, world-class biotech ecosystem.  This landmark
investment affirms our reputation as a global leader in life sciences, while
strengthening the U.S. medicine supply chain, accelerating the development of
life-saving therapies, and creating hundreds of jobs. We are proud to partner
with AstraZeneca to grow our economy and build new pathways to work, wages,
and wealth for all."

 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today marks a
landmark moment for Maryland and American patients. As the state's largest
biopharmaceutical employer, we are deepening our long-standing commitment to
Maryland - supporting 2,600 jobs, catalysing economic growth and bringing our
extensive rare disease portfolio onshore for the first time. This investment
strengthens the resilience of the US medicines supply chain and accelerates
access to transformative therapies for patients across America and around the
world."

 

Today's announcement is part of AstraZeneca's historic $50 billion investment
announced in July and follows a series of US commitments over the past six
months, including unveiling a new cell therapy manufacturing facility in
Rockville, Maryland, a new drug substance manufacturing facility in Virginia
and the expansion of the Company's existing manufacturing facility in Coppell,
Texas.

 

The US is AstraZeneca's largest market by sales and is also home to 19
R&D, manufacturing and commercial sites. The Company's US workforce
exceeds more than 25,000 people and supports more than 100,000 jobs overall
across the country. In 2025, AstraZeneca created approximately $20 billion of
overall value to the American economy.

 

Notes

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Social Media @AstraZeneca
(https://www.linkedin.com/company/astrazeneca) .

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFEESAEEISEIF



            Copyright 2019 Regulatory News Service, all rights reserved